Lumea Inc, a leader in integrated digital pathology solutions, has chosen Tempus, a leader in artificial intelligence and precision medicine, to create AI-enabled solutions that aim to significantly improve the level of care for cancer patients.
Tempus is developing algorithms to detect potential, actionable genetic alterations using whole-slide pathology images on Lumea's digital pathology platform, BxLink®. This technology has the potential to screen cancer patients for clinically actionable biomarkers to identify those within the Lumea system who would benefit from molecular profiling and may qualify for targeted therapies.
"The challenge today is that it is not feasible to screen every cancer patient for specific genetic mutations," stated John Wirthlin, CEO of Lumea. "Tempus' AI technology can digitally screen all patients on Lumea's platform for potential actionable genetic alterations and then identify patients who may benefit from subsequent molecular profiling. This knowledge gives those patients and their physicians the information they need to choose the best treatment options, which will significantly improve patient care."
Tempus will present details of their latest AI-driven, digital pathology work, directly accessible within Lumea's BxLink software as a result of this collaboration, at Lumea's first-of-its-kind Digital Diagnostic Summit this fall in Park City, Utah. There are limited spots available, so register now to learn more exciting digital pathology trends from Tempus, Lumea, and other leaders in the field. You will also have the opportunity to connect with colleagues at the vanguard of high-volume digital pathology implementation.